NCT02239094View on ClinicalTrials.gov

Biosignatures of Latuda for Bipolar Depression

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Bipolar Depression
Interventions
DRUG

Lurasidone (Latuda)

Antipsychotic medication approved for use with Bipolar disorder

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

Sumitomo Pharma America, Inc.

INDUSTRY

lead

New York State Psychiatric Institute

OTHER

NCT02239094 - Biosignatures of Latuda for Bipolar Depression | Biotech Hunter | Biotech Hunter